IDEXX LABORATORIES INC /DE Proceeds from Hedge, Investing Activities
IDEXX LABORATORIES INC /DE (IDXX) reported Proceeds from Hedge, Investing Activities of $2.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromHedgeInvestingActivities · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for the quarter ending 2026-06-30 was $1.04M, a 119.83% increase year-over-year.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for the quarter ending 2026-03-31 was $1.04M, a 149.76% increase year-over-year.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for the quarter ending 2025-12-31 was $1.50M, a 261.54% increase year-over-year.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for the quarter ending 2025-09-30 was $349.00K, a 15.90% decline year-over-year.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for fiscal 2025 was $2.74M, a 76.06% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for fiscal 2024 was $1.56M, a 81.40% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for fiscal 2023 was $8.38M.
- IDEXX LABORATORIES INC /DE proceeds from hedge, investing activities for fiscal 2022 was $0.00.
| Period end | Proceeds from Hedge, Investing Activities 3 month | Proceeds from Hedge, Investing Activities 6 month | Proceeds from Hedge, Investing Activities 9 month | Proceeds from Hedge, Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.08M 10-Q · filed 2026-08-04 | $3.58M derived: sum of 3 quarters · filed 2026-08-04 | $3.93M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.04M 10-Q · filed 2026-05-05 | $2.54M derived: sum of 2 quarters · filed 2026-05-05 | $2.89M derived: sum of 3 quarters · filed 2026-05-05 | $3.37M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.85M derived: sum of 2 quarters · filed 2026-02-20 | $2.33M derived: sum of 3 quarters · filed 2026-08-04 | $2.74M 10-K · filed 2026-02-20 |
| 2025-09-30 | $349.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $823.00K derived: sum of 2 quarters · filed 2026-08-04 | $1.24M 10-Q · filed 2025-11-03 | $1.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $474.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $890.00K 10-Q · filed 2026-08-04 | $1.31M derived: sum of 3 quarters · filed 2026-08-04 | $1.72M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $416.00K 10-Q · filed 2026-05-05 | $832.00K derived: sum of 2 quarters · filed 2026-05-05 | $1.25M derived: sum of 3 quarters · filed 2026-05-05 | $1.65M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $416.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $831.00K derived: sum of 2 quarters · filed 2026-02-20 | $1.23M derived: sum of 3 quarters · filed 2026-02-20 | $1.56M 10-K · filed 2026-02-20 |
| 2024-09-30 | $415.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $813.00K derived: sum of 2 quarters · filed 2025-11-03 | $1.14M 10-Q · filed 2025-11-03 | $3.26M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $398.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $727.00K 10-Q · filed 2025-08-04 | $2.85M derived: sum of 3 quarters · filed 2026-02-20 | $9.10M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $329.00K 10-Q · filed 2025-05-01 | $2.45M derived: sum of 2 quarters · filed 2026-02-20 | $8.71M derived: sum of 3 quarters · filed 2026-02-20 | $8.71M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.38M derived: sum of 2 quarters · filed 2026-02-20 | $8.38M derived: sum of 3 quarters · filed 2026-02-20 | $8.38M 10-K · filed 2026-02-20 |
| 2023-09-30 | $6.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $6.26M derived: sum of 2 quarters · filed 2024-10-31 | $6.26M 10-Q · filed 2024-10-31 | $6.26M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-02-21 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-01 | $0.00 derived: sum of 2 quarters · filed 2025-02-21 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $0.00 10-K · filed 2025-02-21 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |